EFV - iShares MSCI EAFE Value ETF

BATS - BATS Delayed Price. Currency in USD
-1.08 (-1.97%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close54.76
Bid0.00 x 0
Ask0.00 x 0
Day's Range53.65 - 54.24
52 Week Range49.15 - 59.57
Avg. Volume562,811
Net Assets6.58B
PE Ratio (TTM)N/A
YTD Return0.08%
Beta (3y)1.00
Expense Ratio (net)0.40%
Inception Date2005-08-01
  • Barrons.com3 days ago

    Wait for a Bear Before Loading Up on Foreign Stocks

    Waiting for a bear market may seem like waiting for Godot—it’s been 3,297 days since the last bear market ended on March 9, 2009. Ramsey points out that foreign stocks in the MSCI EAFE index have been lagging the U.S. market this year, and they now trade at 26% discount to the MSCI USA index based on “normalized” price/earnings ratios (which smooth out the volatility in earnings over multi-year periods). The EAFE traded at the same discount in May 2010—the start of an “epic phase of underperformance” compared with the U.S. market, he says in a recent blog post.

  • Ideas To Enhance Potential Returns In Global Bull Market Rally
    Investor's Business Daily2 months ago

    Ideas To Enhance Potential Returns In Global Bull Market Rally

    CLS Investments' Rusty Vanneman offers ETF picks for investors with a globally balanced portfolio to enhance potential returns.

  • What’s Teva Pharmaceutical’s Research and Development Strategy?
    Market Realist2 months ago

    What’s Teva Pharmaceutical’s Research and Development Strategy?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.

  • What'll Cause Next Market Downturn?
    ETF.com6 months ago

    What'll Cause Next Market Downturn?

    Risk will likely play an important role.

  • Market Realist6 months ago

    Teva Pharmaceutical on the Street: Analysts’ Recommendations in September

    In August 2017, the FDA approved Teva Pharmaceutical's (TEVA) Austedo for the treatment of adult individuals with tardive dyskinesia.

  • Benzinga7 months ago

    Adding Value To The Developed Markets Trade

    Value stocks in the United States are scuffling against broader benchmarks and growth stocks. While ex-US developed markets value stocks are also trailing relevant benchmarks, the value factor is performing ...

  • Business Wire9 months ago

    BlackRock to Transition Primary Listing Venue for 50 iShares ETFs

    BlackRock will transition the primary listing venue for 50 iShares ETFs.